Cardiac resynchronization therapy improves heart function in cancer survivors

Cardiac resynchronization therapy improves heart function in cancer survivors

A pacemaker-like device restored heart function in a group of cancer survivors - mostly women with breast cancer - who had suffered from heart failure as a result of chemotherapy treatment, a study in the Journal of the American Medical Association (JAMA) reports.

The device was evaluated in a small observational clinical trial, led by the University of Rochester Medical Center, at 12 cardio-oncology programs across the U.S., including at UR Medicine's Wilmot Cancer Institute.

Ties between cancer and heart disease have been in the news lately. Researchers not only suggest that heart disease and cancer risk may be linked, but also that doctors should be aware of heart disease as a side effect of cancer treatment.

Vicki Dennis, 64, of Moravia, N.Y., was a participant in the study and credits it with saving her life.
In the space of a few months, Dennis went from being a healthy, eight-year breast cancer survivor to suddenly having cancer-related heart disease serious enough to land her on a transplant list.

"I proved them all wrong," Dennis said. "I made it through the cancer and now I've made it through this. I think I've astounded everybody in Rochester. I know they've done everything they could for me and now it's just a question of hanging in there - which I intend to do for a long time."

Known as the MADIT-CHIC study, it was the first of its kind to assess whether cardiac resynchronization therapy (CRT) could improve heart function in patients with congestive heart failure and cardiomyopathy, an enlargement of the heart due to chemotherapy side effects.

After six months with the implanted CRT devices, the 30 patients who received cardiac resynchronization therapy experienced significant improvement. The study, which took place between 2014 and 2018, was designed to address a problem that impacts more than half of people who receive anthracycline-based chemotherapies to treat cancer.

These patients are prone to heart muscle damage, and about five percent go into full heart failure, said the study's principal investigator and senior author, Valentina Kutyifa, M.D., Ph.D., associate professor of Medicine at the University of Rochester Clinical Cardiovascular Research Center.

Like Dennis, all of the trial participants did well during six months of follow-up care in the study, Kutyifa said.

"Not only did their heart function improve, but they were able to take care of themselves, enjoy life, and do just about everything they were able to do before the illness," Kutyifa said. "It really gives hope to patients who have survived cancer."

Results from the Rochester-led clinical trial offer a possible solution; JAMA also published an editorial supporting the study and calling for a more "harmonized approach" to cardiac care for cancer survivors.

Heart problems can arise early on - from six months to two years after cancer treatment - or as far as 15 to 20 years, said Eugene Storozynsky, M.D., Ph.D., who specializes in heart complications from cancer treatment. He directs the Cardio-Oncology clinic associated with Wilmot Cancer Institute, the only such program in upstate New York.

Kutyifa said it's important to note that women are more susceptible to heart damage as a chemotherapy side effect. However, women typically represent only about one-third of participants in cardiology studies evaluating implanted devices. For the MADIT-CHIC trial, a concerted effect was made to enroll more women: 87 percent of the participants were females with a mean age of 63, and most had been treated for breast cancer.
The trial's main objective was to evaluate each patient's ejection fraction (EF), a measurement of how much blood is pumped as the heartbeats. A healthy person's EF is typically 60 percent. The study participants had an EF of less than 35 percent when they enrolled - they were in heart failure - and Dennis' EF was a mere 28 percent.

But six months after cardiac resynchronization therapy, Dennis and others in the study saw their EFs rise into the normal range. The CRT erased heart failure symptoms for the vast majority of study participants.

In Dennis' case, 18 months after the start of the trial, her heart had normalized in size and function, even at a microscopic level, said Storozynsky, associate professor of Medicine in cardiology.

"I've seen this only rarely in the 10 years I've been following cancer patients," he said. "She does have a very remarkable story in the sense that if it wasn't for this clinical trial... she may be really struggling."

The opportunities to help patients with cancer and heart problems are growing and the study adds another tool for the future, Storozynsky said. He works with oncologists and internists to identify patients who may be at greater risk, and to minimize the heart's reaction to chemotherapy.

You always want to be aware. If something doesn't seem right, if the heart rate is suddenly higher, that may be an early warning sign. The heart doesn't change from the size of your fist to a football overnight."
Eugene Storozynsky, M.D., Ph.D., associate professor of Medicine in cardiology

Several cancer therapies can impact the heart. In addition to anthracyclines (doxorubicin), which can build up unwanted calcium in the heart muscle, immunotherapy and tyrosine kinase inhibitors can also cause left-ventricle damage. Radiation therapy can lead to a thickening of the heart valves, inflammation, and artery blockages.

UR Medicine doctors established a database to track lymphoma patients treated at Wilmot, who may face risks due to the newer classes of targeted medications that stop the cancer but might induce heart problems, said Ilan Goldenberg, MD., director of UR Medicine's Clinical Cardiovascular Research Center.

"Right now, this is an understudied area," Goldenberg said. "Our plans include collaborating more closely and focusing on how to manage and reverse heart damage caused by many of the newer medications."

The latest research builds on the legacy of renowned University of Rochester cardiologist Arthur J. Moss, who pioneered a vast field of science aimed at preventing and treating sudden death, often with implantable cardiac resynchronization devices. Moss designed and led many successful studies using the CRT in different patient populations. Before he died in 2018, it was Moss' vision to launch the study that saved Dennis' life. He designed the MADIT-CHIC trial in 2014 with the study's corresponding author Jagmeet Singh, M.D., Ph.D., professor of Medicine at Harvard Medical School.

Boston Scientific, the device maker, funded the trial with an investigator-initiated research grant. The Brigham Women's Hospital in Boston served as the central echocardiography core laboratory.

University of Rochester Medical Center.

Journal reference:
Singh, J.P., et al. (2019) Association of Cardiac Resynchronization Therapy With Change in Left Ventricular Ejection Fraction in Patients With Chemotherapy-Induced Cardiomyopathy. JAMA.

No comments